Study to monitor the emergence of SARS-CoV-2 spike viral variants

• Research type

  Research Study

• Full title

  Prospective cohort study to monitor the emergence of SARS-CoV-2 spike viral variants in immunocompromised non-hospitalised patients exposed to sotrovimab in Great Britain: LUNAR study

• IRAS ID

  1005346

• Contact name

  Myriam Drysdale

• Contact email

  myriam.g.drysdale@gsk.com

• Sponsor organisation

  GlaxoSmithKline Research and Development Limited

• Eudract number

  2022-000754-29

• ISRCTN Number

  ISRCTN74418247

• Research summary

  This is a safety surveillance study, requested by MHRA, to monitor any SARS-CoV-2 viral variants on non hospitalised, immunosuppressed COVID-19 patients.

• REC name

  South Central - Oxford B Research Ethics Committee

• REC reference

  22/SC/0099

• Date of REC Opinion

  12 May 2022

• REC opinion

  Further Information Favourable Opinion